HIV-1 Treatment-as-Prevention

AbstractThe Chinese national observational cohort study suggests that the treatment-as-prevention (TasP) approach can be an effective public health HIV-1 prevention strategy. However, results from that study may have been biased because the follow-up time of index patients prior to their initiation of antiretroviral therapy (ART) was excluded. In this study, we correct for such bias by using an extended time-dependent Cox regression model to conduct a cohort study analysis of serodiscordant couples in Guangxi of China, inclusive of all follow-up time.During the follow-up of this observational cohort study of HIV-1 sero-discordant couples, the positive index partners may have never be treated with ART, or enter untreated but subsequently began treatment, or may have been treated immediately upon entry into the public health system. The treatment effectiveness of ART in HIV-1 acquisition among HIV-negative partners is assessed by the extended Cox regression model with treatment status as a time-varying covariate.A total of 6548 sero-discordant couples were included in the cohort study analysis. Among them, 348 negative partners sero-converted. HIV seroincidence was significantly higher among the nontreated (4.3 per 100 person-years, 3.7–4.9) compared with those receiving ART (1.8 per 100 person-years, 1.5–2.0). An overall 35% reduction in risk of HIV transmission was associated with receiving ART (adjusted hazard ratio [AHR] 0.65, 95% confidence interval [CI] 0.51–0.83), and the yearly risk reduction was also significant in the first 3 consecutive years of follow-up. Moreover, ART was found to be significantly inversely associated with multiple baseline characteristics of index partners.TasP may be feasible on a national or regional scale. In addition to other proven preventive strategies such as the use of condoms, ART adherence to maintain viral suppression would then be the key challenge for successful TasP implementation.

[1]  H. Xing,et al.  HIV, Syphilis, and Behavioral Risk Factors among Female Sex Workers before and after Implementation of Harm Reduction Programs in a High Drug-Using Area of China , 2014, PloS one.

[2]  J. Montaner,et al.  Antiretroviral Therapy Reduces HIV Transmission in Discordant Couples in Rural Yunnan, China , 2013, PloS one.

[3]  Yiming Shao,et al.  Antiretroviral therapy to prevent HIV transmission in serodiscordant couples in China (2003–11): a national observational cohort study , 2013, The Lancet.

[4]  Ning Wang,et al.  Heterosexual transmission of HIV and related risk factors among serodiscordant couples in Henan province, China , 2013, Chinese medical journal.

[5]  S. Cole,et al.  Decreasing Excess Mortality of HIV-Infected Patients Initiating Antiretroviral Therapy: Comparison with Mortality in General Population in China, 2003–2009 , 2013, Journal of acquired immune deficiency syndromes.

[6]  S. Vermund,et al.  Impact of HIV drug resistance on virologic and immunologic failure and mortality in a cohort of patients on antiretroviral therapy in China , 2013, AIDS.

[7]  W. Liu,et al.  Incidence and Associated Factors of HIV Drug Resistance in Chinese HIV-Infected Patients Receiving Antiretroviral Treatment , 2013, PloS one.

[8]  H. Xing,et al.  Evaluation of Harm Reduction Programs on Seroincidence of HIV, Hepatitis B and C, and Syphilis Among Intravenous Drug Users in Southwest China , 2013, Sexually transmitted diseases.

[9]  W. Liu,et al.  HIV Drug Resistance and Its Impact on Antiretroviral Therapy in Chinese HIV-Infected Patients , 2013, PloS one.

[10]  Ning Wang,et al.  HIV seroconversion and prevalence rates in heterosexual discordant couples in China: A systematic review and meta-analysis , 2012, AIDS care.

[11]  S. Cole,et al.  Attrition among Human Immunodeficiency Virus (HIV)- Infected Patients Initiating Antiretroviral Therapy in China, 2003–2010 , 2012, PloS one.

[12]  S. Swindells,et al.  Prevention of HIV-1 infection with early antiretroviral therapy , 2011, Journal of Family Planning and Reproductive Health Care.

[13]  Shuntai Zhou,et al.  Effect of earlier initiation of antiretroviral treatment and increased treatment coverage on HIV-related mortality in China: a national observational cohort study. , 2011, The Lancet. Infectious diseases.

[14]  Yan Gao,et al.  Design and implementation of a China comprehensive AIDS response programme (China CARES), 2003–08 , 2010, International journal of epidemiology.

[15]  Ray Y. Chen,et al.  Cohort profile: the Chinese national free antiretroviral treatment cohort. , 2010, International journal of epidemiology.

[16]  Delpech,et al.  Long-term probability of detecting drug-resistant HIV in treatment-naive patients initiating combination antiretroviral therapy. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  H. Xing,et al.  The Prevalence of Transmitted Antiretroviral Drug Resistance in Treatment-Naive HIV-Infected Individuals in China , 2010, Journal of acquired immune deficiency syndromes.

[18]  Ray Y. Chen,et al.  Five-Year Outcomes of the China National Free Antiretroviral Treatment Program , 2009, Annals of Internal Medicine.

[19]  C. Armon,et al.  Initiation of HAART at Higher CD4 Cell Counts Is Associated With a Lower Frequency of Antiretroviral Drug Resistance Mutations at Virologic Failure , 2009, Journal of acquired immune deficiency syndromes.

[20]  Jiahong Xu,et al.  The effect of highly active antiretroviral therapy on mortality among HIV-infected former plasma donors in China. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  S. Lai,et al.  HIV Incidence, Retention, and Changes of High-Risk Behaviors Among Rural Injection Drug Users in Guangxi, China , 2007, Substance abuse.

[22]  M. Kozal,et al.  A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial , 2006, The Lancet.

[23]  O. Laeyendecker,et al.  Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. , 2005, The Journal of infectious diseases.

[24]  S. Twu,et al.  Decreased HIV transmission after a policy of providing free access to highly active antiretroviral therapy in Taiwan. , 2004, The Journal of infectious diseases.

[25]  S. Vermund,et al.  Virologic and immunologic determinants of heterosexual transmission of human immunodeficiency virus type 1 in Africa. , 2001, AIDS research and human retroviruses.

[26]  S. Lai,et al.  Changes in HIV‐1 Incidence in Heroin Users in Guangxi Province, China , 2001, Journal of acquired immune deficiency syndromes.

[27]  S. Lai,et al.  Changes in HIV-1 incidence in heroin users in Guangxi Province, China. , 2001 .

[28]  S. Lai,et al.  Adoption of Injection Practices in Heroin Users in Guangxi Province, China , 2000, Journal of psychoactive drugs.

[29]  Hiv Survival,et al.  Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis , 2000, The Lancet.

[30]  T. Quinn,et al.  Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. , 2000, The New England journal of medicine.

[31]  Jie Chen,et al.  Overland heroin trafficking routes and HIV-1 spread in south and south-east Asia , 2000, AIDS.

[32]  W. Liu,et al.  Emerging HIV infections with distinct subtypes of HIV-1 infection among injection drug users from geographically separate locations in Guangxi Province, China. , 1999, Journal of acquired immune deficiency syndromes.

[33]  S. Lai,et al.  Two subtypes of HIV-1 among injection-drug users in southern China , 1998, The Lancet.